Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Sep;168(3):959-61.
doi: 10.1016/S0022-5347(05)64551-X.

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers

B Escudier  1 , J P Droz, F Rolland, M J Terrier-Lacombe, G Gravis, P Beuzeboc, B Chauvet, C Chevreau, J C Eymard, T Lesimple, Y Merrouche, S Oudard, F Priou, C Guillemare, S Gourgou, S Culine; Genitourinary Group of the French Federation of Cancer Centers
Affiliations
Clinical Trial

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers

B Escudier et al. J Urol. 2002 Sep.

Abstract

Purpose: We assessed the efficacy and toxicity of a chemotherapy regimen combining doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma.

Materials and methods: Of the 25 patients included in a prospective multicenter phase II trial 23 were evaluable for efficacy and toxicity studies after pathological review.

Results: A median of 3 cycles per patient (range 1 to 8) was administered. No objective response was observed. Median time to progression was 2.2 months and median overall survival was 3.9 months. A single patient died of toxicity.

Conclusions: The results do not support the standard use of doxorubicin/ifosfamide chemotherapy in patients with metastatic sarcomatoid renal cell carcinoma.

PubMed Disclaimer

MeSH terms